18
Apr
The Countdown to Nitrosamine Impurity Compliance - Lachman Blog

The Countdown to Nitrosamine Impurity Compliance in the U.S. Has Begun

Lachman has blogged many times on the topic of nitrosamines over the last several years as the FDA has issued and revised guidances providing its recommendations for assessment and control of nitrosamine impurities. The published deadline for compliance with these recommendations is quickly approaching; it’s just over three months until the August 1, 2025 compliance date […]

Read More
14
Apr
Do You Trust What Your Drug Applications are Saying - Lachman Blog

Do You Trust What Your Drug Applications are Saying?

Trust is essential to everything we do in the pharmaceutical industry. Developing new drugs requires speaking the global language of data, which is meaningless without trust. Toxicity, efficacy, bioequivalence, and bioavailability are key measurements of drug safety and effectiveness, all spoken in the language of data. These only have meaning if there is trust. Imagine […]

Read More
07
Apr
Horses

All’s Quiet on the Eastern Front! Mostly from OGD

Given all that’s happened with the federal government this past week, it’s no wonder that we’re not hearing much from the OGD.  Communications appear to be quite slow to appear.  Even the Federal Register prepublication page has few FDA postings over the last three weeks.  Another instance of communication lapse: since March 7, 2025, only safety […]

Read More
03
Apr
Bx Rating - Lachman Blog

FDA Issues Notice to Pharmaceutical Companies Regarding the CRO Raptim Research Pvt. Ltd.

On March 28, the FDA issued a notice (here) informing pharmaceutical companies that have submitted in vitro and in vivo bioequivalence studies in applications that were conducted by Raptim Research Pvt. Ltd., a contract research organization (CRO) based in Navi Mumbai, India, that it has “identified significant data integrity and study conduct concerns” in certain studies in […]

Read More
13
Mar
The Benzene Frenzy - Lachman Blog

The Benzene Frenzy: FDA Testing Reveals that the Extent of the Issue Appears Much More Limited Than Previously Thought

After a March 6, 2025 report from an independent testing facility claimed that a significant number of acne products containing benzoyl peroxide were found to have very high levels of benzene (here), the threat has been countered by the FDA’s own testing of 95 products. After the FDA’s testing results were confirmed, it announced that the “FDA […]

Read More
25
Feb
Is the Freeze Beginning to Thaw - Lachman Blog

Is the Freeze Beginning to Thaw?

There is a hint that the “pause” or freeze on communications from the FDA may be starting to thaw. This morning, a CDER Small Business and Industry Assistance (SBIA) Webinar titled Navigating Controlled Correspondences to Support Generic Drug Development, to be held on February 27, 2025 from 1:00 to 3:30 p.m., was posted with a request […]

Read More
12
Feb
An unhappy female student sitting on sofa, tearing paper when studying.

Regulatory Agendas for Various Agencies Disappeared from Federal Register

I guess this is the next step in the evaluation of what we can expect regarding proposals for future regulations.  Semiannual regulatory agendas, along with tentative timetables, are published twice a year (as the name implies) to outline regulations that each agency is planning on issuing for those regulations. Today, in the pre-publication of the […]

Read More
1 … 8 9 10 … 35